.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
DRCR Retina Network Protocol V addressed an important clinical question: how aggressively should clinicians treat center-involving diabetic macular edema when visual acuity is still good? The randomized trial compared initial aflibercept, focal/grid laser, and observation in eyes with center-involving DME and good visual acuity. The results showed that an immediate injection strategy did not produce a clinically important visual-acuity advantage over observation or laser at the population level when rescue aflibercept was available for prespecified visual decline. The study helped reinforce a more individualized approach to treatment, where OCT anatomy and visual function are interpreted together rather than automatically triggering injections for every center-involving edema finding. For clinicians, this is especially useful in patients with preserved central vision, where injection burden, patient preference, treatment access, and the likelihood of progression all matter. Protocol V does not mean that DME should be ignored; it supports structured monitoring and timely initiation of anti-VEGF when visual loss develops. The study therefore remains a practical framework for balancing overtreatment against the risk of delayed intervention.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
DRCR Retina Network Protocol V addressed an important clinical question: how aggressively should clinicians treat center-involving diabetic macular edema when visual acuity is still good? The randomized trial compared initial aflibercept, focal/grid laser, and observation in eyes with center-involving DME and good visual acuity. The results showed that an immediate injection strategy did not produce a clinically important visual-acuity advantage over observation or laser at the population level when rescue aflibercept was available for prespecified visual decline. The study helped reinforce a more individualized approach to treatment, where OCT anatomy and visual function are interpreted together rather than automatically triggering injections for every center-involving edema finding. For clinicians, this is especially useful in patients with preserved central vision, where injection burden, patient preference, treatment access, and the likelihood of progression all matter. Protocol V does not mean that DME should be ignored; it supports structured monitoring and timely initiation of anti-VEGF when visual loss develops. The study therefore remains a practical framework for balancing overtreatment against the risk of delayed intervention.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
